Table 2.
EULAR responses at next reevaluation after first RA flare.
| EULAR response | ||||
|---|---|---|---|---|
| No | Moderate | Good | P | |
| RTX | ||||
| Group A | 4 (16%) | 5 (20%) | 7 (28%) | 0.038 |
| Group B | 6 (24%) | 2 (10%) | 1 (4%) | |
| IFX | ||||
| Group A | 2 (10%) | 5 (25%) | 2 (10%) | 0.002 |
| Group B | 10 (50%) | 1 (5%) | 0 | |
| ETN | ||||
| Group A | 3 (16.67%) | 5 (27.78%) | 7 (38.89%) | 0.023 |
| Group B | 3 (16.67%) | 0 | 0 | |
| ADL | ||||
| Group A | 2 (22.22%) | 1 (11.11%) | 5 (55.56%) | 0.194 |
| Group B | 1 (11.11%) | 0 | 0 | |
Differences between EULAR responses in group A and group B were tested using Kruskal-Wallis test, for each biologic agent.
RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab.
Group A: detectable drug level; Group B: undetectable drug level.